Crossmark

Effect of subcutaneous vs. intravenous tocilizumab in patients with severe COVID-19: a systematic review

Published Online: 2024-06-27

Published Print: 2024-10

Authors

Li, Yun

Li, Xianlin

Zheng, Xiaojun https://orcid.org/0009-0001-0535-5076
License Information

Text and Data Mining valid from 2024-06-27

Version of Record valid from 2024-06-27
More Information

Article History

Received: 15 May 2024

Accepted: 21 June 2024

First Online: 27 June 2024

Declarations

:

: The study is deemed exempt to receive ethical approval.

: Not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current